TP 452

Drug Profile

TP 452

Alternative Names: DPA free fatty acid - Thetis; DPA-FFA – Thetis

Latest Information Update: 08 Feb 2016

Price : $50

At a glance

  • Originator Thetis Pharmaceuticals
  • Class Antihyperlipidaemics; Omega 3 fatty acids
  • Mechanism of Action HMG-CoA reductase inhibitors; PCSK9 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hypercholesterolaemia

Most Recent Events

  • 27 Jan 2016 Thetis plans a phase I trial for Hypercholesterolaemia in USA
  • 27 Jan 2016 Thetis Pharmaceuticals has patent protection for TP 452 in USA
  • 04 Aug 2015 Thetis receives patent allowance for composition of matter of TP 452 in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top